{"id":"https://openalex.org/A5111362020","orcid":null,"observed_orcids":[],"display_name":"Malakai Miller","raw_author_names":["Malakai Miller"],"full_name":"Malakai Miller","works_count":6,"cited_by_count":1,"summary_stats":{"2yr_mean_citedness":0.16666666666666666,"h_index":1,"i10_index":0},"ids":{"openalex":"https://openalex.org/A5111362020","orcid":null,"observed_orcids":[]},"affiliations":[{"institution":{"id":"https://openalex.org/I4210128310","ror":"https://ror.org/03wmmfz90","display_name":"Tennessee Department of Health","country_code":"US","type":"government","lineage":["https://openalex.org/I4210128310"]},"years":[2026,2024]}],"last_known_institutions":[{"id":"https://openalex.org/I4210128310","ror":"https://ror.org/03wmmfz90","display_name":"Tennessee Department of Health","country_code":"US","type":"government","lineage":["https://openalex.org/I4210128310"]}],"topics":[{"id":"https://openalex.org/T11000","display_name":"Infection Control in Healthcare","count":4,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11288","display_name":"Clostridium difficile and Clostridium perfringens research","count":4,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10897","display_name":"Antibiotic Use and Resistance","count":3,"subfield":{"id":"https://openalex.org/subfields/2402","display_name":"Applied Microbiology and Biotechnology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","count":2,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","count":2,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"topic_share":[{"id":"https://openalex.org/T11288","display_name":"Clostridium difficile and Clostridium perfringens research","value":3.44e-05,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11000","display_name":"Infection Control in Healthcare","value":1.07e-05,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10897","display_name":"Antibiotic Use and Resistance","value":9e-06,"subfield":{"id":"https://openalex.org/subfields/2402","display_name":"Applied Microbiology and Biotechnology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","value":8.4e-06,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","value":7.9e-06,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"x_concepts":[{"id":"71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","score":0.972000002861023},{"id":"126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","score":0.6133000254631042},{"id":"2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","score":0.5776000022888184},{"id":"177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","score":0.48919999599456787},{"id":"194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","score":0.4754999876022339}],"counts_by_year":[{"year":2024,"works_count":1,"oa_works_count":1,"cited_by_count":0},{"year":2026,"works_count":5,"oa_works_count":4,"cited_by_count":1}],"display_name_alternatives":["Malakai Miller"],"block_key":"m miller","works_api_url":"https://api.openalex.org/works?filter=author.id:A5111362020","updated_date":"2026-10-10T12:59:14","created_date":"2025-10-10T00:00:00"}